Literature DB >> 31473094

Association between CTLA-4 gene polymorphism and myasthenia gravis in a Chinese cohort.

Gao-Mei Cai1, Zhe Gao2, Yao-Xian Yue3, Yan-Chen Xie4, Xiang Gao5, Hong-Jun Hao6, Xian-Jun Zhang5, Qi Wang5, Bing Liang3, Hai-Feng Li7.   

Abstract

Abnormal CTLA-4 expression is involved in the development of myasthenia gravis (MG), and serum CTLA-4 levels are positively correlated with serum anti-AChR antibody concentration, which might be related with the severity of MG. Polymorphism in CTLA-4 gene is associated with various autoimmune disorders. We investigated the association of polymorphism in CTLA-4 gene with the clinical variables and severity of MG. The frequencies of alleles and genotypes were compared between 480 MG patients and 487 healthy controls, as well as among subgroups of MG patients. The frequency of rs733618*C allele is significantly higher in MG group and several subgroups than in control group. Genotype is not found as independent factor for essential clinical variables of MG. The frequency of rs231775*A allele is significantly lower in ocular onset subgroup than in control group, and the frequencies of rs231775*A allele and rs3087243*A allele are significantly lower in ocular onset subgroup than in generalized onset subgroup. Genotypes of the two SNPs are found as independent factors for ocular onset. The frequency of rs231775*A allele is significantly lower in mild subgroup than that in control group. Genotype is not found as independent factor for mild severity. A haplotype containing rs733618*C, rs231775*G and rs3087243*G is identified to increase the general risk of MG by 1.278-fold and ocular onset MG subgroup by 1.362-fold. There is association of rs733618 with the general susceptibility of MG, and association of rs231775 and rs3087243 with the susceptibility of ocular onset MG, but no association with the severity of MG.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytotoxic T lymphocyte associated antigen-4; Myasthenia gravis; Polymorphism; Severity; Susceptibility

Year:  2019        PMID: 31473094     DOI: 10.1016/j.jocn.2019.08.079

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  3 in total

1.  Identification of the regulatory role of lncRNA HCG18 in myasthenia gravis by integrated bioinformatics and experimental analyses.

Authors:  Shuang Li; Xu Wang; Tianfeng Wang; Huixue Zhang; Xiaoyu Lu; Li Liu; Lifang Li; Chunrui Bo; Xiaotong Kong; Si Xu; Shangwei Ning; Jianjian Wang; Lihua Wang
Journal:  J Transl Med       Date:  2021-11-18       Impact factor: 5.531

2.  Competitive endogenous RNA network and pathway-based analysis of LncRNA single-nucleotide polymorphism in myasthenia gravis.

Authors:  Tianfeng Wang; Si Xu; Huixue Zhang; Xiaoyu Lu; Shuang Li; Li Liu; Xiaotong Kong; Hongyu Gao; Xu Wang; Shangwei Ning; Jianjian Wang; Lihua Wang
Journal:  Sci Rep       Date:  2021-12-14       Impact factor: 4.379

Review 3.  Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy.

Authors:  Adrian Chye; India Allen; Megan Barnet; Deborah L Burnett
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.